{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:58:36Z","timestamp":1792569516147,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,2]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>TAFRO syndrome is a systemic inflammatory disorder, manifesting as thrombocytopenia (t), anasarca (a), fever (f), reticulin myelofibrosis\/renal insufficiency (r), and organomegaly (o), and considered as a unique clinical subtype of idiopathic multicentric Castleman disease (iMCD). Such syndrome gave rise to a clinical picture similar to that of either a connective tissue disease or an autoimmune disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A Chinese young female initially presenting with arthralgia, Raynaud phenomenon, generalized edema, and a positive anti-small nuclear ribonucleoprotein particle antibody was diagnosed as mixed connective tissue disease. The kidney biopsy showed thrombotic microangiopathy. Bone marrow smear showed bone marrow hyperplasia and biopsy revealed suspected light chain restricted expression, megakaryocyte proliferation, and moderate to severe bone marrow fibrosis. A lymph node biopsy was conducted and the histopathological findings were consistent with the subtype of mixed Castleman disease. The clinical symptoms were relieved after regular chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>After above examination results and clinical manifestations, the final diagnoses was TAFRO syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>The she was started on chemotherapy with bortezomib, cyclophosphamide, and dexamethasone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcome:<\/jats:title>\n            <jats:p>After chemotherapy, symptoms such as thrombocytopenia, hematuria and proteinuria disappeared, lymphadenopathy and VEGF level decreased, and bone marrow fibrosis relieved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Our case illustrated the first cases of shared characteristics of mixed connective tissue disease and iMCD-TAFRO syndrome. Cytokines may play a role in the shared pathogenicity of the iMCD-TAFRO syndrome and systemic autoimmune diseases. Therapy directly against inflammatory factors such as corticosteroids or chemotherapy have an important therapeutic implication.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039148","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:19:50Z","timestamp":1722619190000},"page":"e39148","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Delayed diagnosis of TAFRO syndrome: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2182-1180","authenticated-orcid":false,"given":"Yumeng","family":"Qiao","sequence":"first","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China"},{"name":"Institute of Nephrology, Peking University, Beijing, China"},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China"},{"name":"Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China"},{"name":"Institute of Nephrology, Peking University, Beijing, China"},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China"},{"name":"Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China"},{"name":"Institute of Nephrology, Peking University, Beijing, China"},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China"},{"name":"Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Jia","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China"},{"name":"Institute of Nephrology, Peking University, Beijing, China"},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China"},{"name":"Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University First Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am J Hematol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3960\/jslrt.19021","article-title":"Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan.","volume":"59","author":"Masaki","year":"2019","journal-title":"J Clin Exp Hematopathol"},{"key":"R4-20250503","first-page":"320","article-title":"[Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly].","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome.","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"R6-20250503","first-page":"543","article-title":"Clinical features of patients with castleman\u2019s disease complicated systemic lupus erythematosus.","volume":"38","author":"Zhang","year":"2016","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0344-0338(97)80015-5","article-title":"Systemic lupus erythematosus (SLE) lymphadenopathy presenting with histopathologic features of Castleman\u2019 disease: a clinicopathologic study of five cases.","volume":"193","author":"Kojima","year":"1997","journal-title":"Pathol Res Pract"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00296-010-1451-0","article-title":"A case report of systemic lupus erythematosus combined with Castleman\u2019s disease and literature review.","volume":"32","author":"Xia","year":"2012","journal-title":"Rheumatol Int"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.prp.2007.03.002","article-title":"Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients.","volume":"203","author":"Kojima","year":"2007","journal-title":"Pathol Res Pract"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1097\/MD.0000000000000741","article-title":"Autoimmune myelofibrosis and systemic lupus erythematosus in a middle-aged male presenting only with severe anemia: a case report.","volume":"94","author":"Pundole","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2183\/pjab.86.717","article-title":"Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir.","volume":"86","author":"Hirano","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon gamma-induced protein 10\u2009kDa is associated with TAFRO syndrome.","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"key":"R13-20250503","first-page":"R3","article-title":"Systemic connective tissue disease complicated by Castleman\u2019s disease: report of a case and review of the literature.","volume":"89","author":"De Marchi","year":"2004","journal-title":"Haematologica"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","article-title":"TAFRO syndrome.","volume":"32","author":"Igawa","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12882-019-1574-9","article-title":"TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.","volume":"20","author":"Nagayama","year":"2019","journal-title":"BMC Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:11:39Z","timestamp":1746317499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":15,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039148","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}